Primmune Therapeutics is focused on harnessing the power of innate immunity to develop innovative treatments for cancer, particularly through the activation of plasmacytoid dendritic cells (pDCs) via the toll-like receptor 7 (TLR7) pathway. Their lead candidate, PRTX007, is a novel oral TLR7 agonist designed to selectively activate pDCs, which play a crucial role in the immune response against tumors and viral infections. By stimulating pDCs, PRTX007 aims to enhance both innate and adaptive immune responses while minimizing the production of pro-inflammatory cytokines, thereby reducing potential side effects associated with traditional immunotherapies.

The technology behind PRTX007 allows for a controlled and sustained immune response, which is essential for effective cancer treatment. Preclinical studies have shown that PRTX007 can activate target cells systemically without triggering the adverse effects commonly associated with pro-inflammatory cytokines. This innovative approach not only aims to reverse immunosuppression in the tumor microenvironment but also enhances immune surveillance by activating circulating pDCs. Primmune is advancing PRTX007 towards clinical trials, particularly targeting HPV-related oropharyngeal cancers and hepatocellular carcinoma, addressing significant unmet medical needs in oncology.

United States

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.

Primmune Therapeutics

Company Details